TY - JOUR T1 - Nonpharmacological interventions in COPD JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0028-2023 VL - 32 IS - 167 SP - 230028 AU - Wim Janssens AU - Geert M. Verleden Y1 - 2023/03/31 UR - http://err.ersjournals.com/content/32/167/230028.abstract N2 - COPD is recognised as one of the major health challenges for the coming decades. This is primarily driven by a growing burden of the disease due to persistent exposure to tobacco smoke and environmental pollutants, an ageing population, and no curative therapies to date. To change the disease course, to reduce its societal impact and eventually eliminate the disease, a recent Lancet commission paper made a plea for a complete rethinking of our current approach in COPD [1]. One of the six major challenges identified is the huge unmet need for a personalised approach based on a holistic assessment of pathophysiological traits, clinical symptoms and patients’ needs. Current pharmacological therapies may improve respiratory symptoms, quality of life and reduce exacerbation frequency, but the majority of COPD patients remain highly symptomatic despite optimised drug combinations and innovative inhalers.In COPD, a holistic and yet personalised approach is mandatory if we want to improve risk management, to control symptoms and achieve disease remission. Global access to nonpharmacological interventions will be essential for these ambitious targets. https://bit.ly/3k7aGAa ER -